Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Perjeta Injectable Product|DRUG: Herceptin|DRUG: Tamoxifen|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Leuprorelin acetate|DRUG: Goserelin|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Paclitaxel|DRUG: Tamoxifen|DRUG: Leuporelin acetate|DRUG: Goserelin|DIAGNOSTIC_TEST: Biopsy|PROCEDURE: Surgery
Sponsor: Palleos Healthcare GmbH
Collaborators: Roche Pharma AG|WSG WOMEN´S HEALTHCARE STUDY GROUP|Cankado GmbH